Mar 28 |
We're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate
|
Mar 27 |
Aura Biosciences GAAP EPS of -$1.93
|
Mar 27 |
Aura Biosciences files $350M mixed securities shelf
|
Mar 27 |
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
|
Mar 17 |
11 Oversold Biotech Stocks To Buy Right Now
|
Feb 26 |
Aura Biosciences to Participate in Upcoming Investor Conferences
|
Jan 7 |
Owning 48% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA),
|
Dec 11 |
Wall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a Bet
|
Dec 7 |
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
|
Nov 23 |
Wall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to Trade
|